Shah Rukh Khan, Ajay Devgn, Tiger Shroff yet to reply to notice on advertisement: FDA Commissioner Tukaram Mundhe
Source Entity
Latest News: Todays Latest News Headlines from India & World | Hindustan Times | Hindustan Times
Maharashtra FDA Commissioner Tukaram Mundhe has issued show-cause notices to Shah Rukh Khan, Ajay Devgn, and Tiger Shroff regarding their involvement in surrogate advertising for a pan masala brand. Mundhe clarified that these actions are strictly based on 2018 food safety regulations that hold promoters accountable, rather than a personal vendetta.
Regulatory Scrutiny: Bollywood Stars Under the FDA Lens
The Maharashtra Food and Drug Administration (FDA), led by Commissioner Tukaram Mundhe, has initiated a significant legal push against some of Bollywood's biggest names—Shah Rukh Khan, Ajay Devgn, and Tiger Shroff. The core of this controversy lies in the actors' participation in advertisements for Vimal Elaichi, a product that authorities allege serves as a form of surrogate advertising for tobacco-related goods. This regulatory move has sparked a wider conversation about the ethical and legal boundaries of celebrity endorsements in India.
The Legal Basis: 2018 Food Safety Regulations
Commissioner Mundhe has been vocal in clarifying that these notices are not a targeted campaign to generate publicity or harass individual celebrities. Instead, he points to the Food Safety and Standards (Advertising and Claims) Regulations of 2018. According to these rules, the responsibility for the truthfulness and safety of an advertised product does not rest solely with the manufacturer. Promoters and endorsers share a significant portion of this liability, effectively making them accountable for the products they choose to represent in the public domain.
Defining Surrogate Advertising
Surrogate advertising remains a complex issue within the Indian media landscape. Brands often promote prohibited products like tobacco or alcohol under the guise of peripheral items such as mouth fresheners or soda. By leveraging the immense influence of A-list actors, these companies manage to keep their primary brands at the forefront of consumer consciousness. The FDA’s current stance suggests a shift toward stricter enforcement of existing laws to curb this practice, emphasizing that 'truthful' promotion is a legal mandate rather than a suggestion.
Addressing the 'Targeting' Allegations
Critics have questioned why the FDA is focusing on high-profile actors rather than the manufacturers themselves. Mundhe has countered this by asserting that the FDA is simultaneously pursuing action against manufacturers and sellers. By holding both the companies and the celebrity endorsers accountable, the agency aims to create a systemic deterrent against deceptive marketing practices. This dual-pronged approach is intended to ensure that the regulatory framework established in 2019 is fully realized.
The Future of Celebrity Accountability
The silence from the actors regarding the notices has only intensified the spotlight on this issue. As the FDA continues to monitor advertisements across television, social media, and print, the precedent set by these notices may fundamentally alter how Bollywood stars approach brand partnerships. Moving forward, celebrities may be forced to conduct more rigorous due diligence before signing contracts, knowing that the regulatory environment is no longer lenient toward surrogate claims.
Conclusion
Ultimately, the conflict between the Maharashtra FDA and these prominent actors serves as a test case for India’s food safety and advertising regulations. While the debate regarding individual responsibility versus corporate accountability will continue, the FDA’s firm adherence to the 2018 guidelines signals a new era of enforcement. Whether this leads to a reduction in surrogate advertising or a prolonged legal battle remains to be seen, but the message from the regulators is clear: the law applies equally to those who promote products as it does to those who manufacture them.
Verification Required?